DK1272527T3 - Fremstilling af antistoffer med ADCC via CD16 og især monoklonale anti-Rhesus D-antistoffer - Google Patents
Fremstilling af antistoffer med ADCC via CD16 og især monoklonale anti-Rhesus D-antistofferInfo
- Publication number
- DK1272527T3 DK1272527T3 DK01927974T DK01927974T DK1272527T3 DK 1272527 T3 DK1272527 T3 DK 1272527T3 DK 01927974 T DK01927974 T DK 01927974T DK 01927974 T DK01927974 T DK 01927974T DK 1272527 T3 DK1272527 T3 DK 1272527T3
- Authority
- DK
- Denmark
- Prior art keywords
- mab
- antibodies
- effector cells
- preparation
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0004685A FR2807767B1 (fr) | 2000-04-12 | 2000-04-12 | Anticorps monoclonaux anti-d |
PCT/FR2001/001127 WO2001077181A2 (fr) | 2000-04-12 | 2001-04-12 | Anticorps monoclonaux anti-rhesus d |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1272527T3 true DK1272527T3 (da) | 2009-05-04 |
DK1272527T4 DK1272527T4 (da) | 2019-01-02 |
Family
ID=8849165
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01927974.4T DK1272527T4 (da) | 2000-04-12 | 2001-04-12 | Fremstilling af antistoffer med adcc via cd16 og især monoklonale anti-rhesus d-antistoffer |
DK10180551.3T DK2341078T3 (da) | 2000-04-12 | 2001-04-12 | Antistoffer med forbedret ADCC-aktivitet |
DK04028814.4T DK1518864T4 (da) | 2000-04-12 | 2001-04-12 | Sammensætning af antistoffer med høj ADCC |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10180551.3T DK2341078T3 (da) | 2000-04-12 | 2001-04-12 | Antistoffer med forbedret ADCC-aktivitet |
DK04028814.4T DK1518864T4 (da) | 2000-04-12 | 2001-04-12 | Sammensætning af antistoffer med høj ADCC |
Country Status (11)
Country | Link |
---|---|
US (13) | US7579170B2 (da) |
EP (4) | EP2341078B1 (da) |
JP (9) | JP5192625B2 (da) |
AT (1) | ATE419276T2 (da) |
AU (3) | AU2001254858B2 (da) |
CA (1) | CA2406033C (da) |
DE (1) | DE60137210D1 (da) |
DK (3) | DK1272527T4 (da) |
ES (3) | ES2525762T5 (da) |
FR (1) | FR2807767B1 (da) |
WO (1) | WO2001077181A2 (da) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US7749753B2 (en) * | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
FR2844520B1 (fr) * | 2002-09-13 | 2006-06-09 | Lab Francais Du Fractionnement | Utilisation d'un anticorps induisant la secretion de cytokines en therapie |
FR2844521B1 (fr) * | 2002-09-13 | 2004-12-24 | Lab Francais Du Fractionnement | Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices |
CA2498315C (fr) * | 2002-09-13 | 2013-01-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps induisant la production de cytokines |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
WO2004087757A2 (en) * | 2003-04-03 | 2004-10-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Antibodies with enhanced ability to immunomodulate cell functions |
FR2858235B1 (fr) * | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
FR2861078B1 (fr) * | 2003-10-16 | 2007-09-21 | Lab Francais Du Fractionnement | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
GB0324368D0 (en) * | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
FR2861079B1 (fr) * | 2003-10-20 | 2007-09-28 | Lab Francais Du Fractionnement | Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps. |
FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
EP1720570A4 (en) * | 2004-01-26 | 2008-09-03 | Cangene Corp | TREATMENT OF DENGUE H MORRAGIC FIUR |
WO2005117270A2 (en) | 2004-05-24 | 2005-12-08 | Isis Pharmaceuticals, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
CA2624081C (en) * | 2005-09-29 | 2014-09-16 | Medimmune, Inc. | Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
CA2626542C (en) * | 2005-10-21 | 2018-07-03 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
ATE536373T1 (de) * | 2005-10-21 | 2011-12-15 | Genzyme Corp | Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität |
FR2895086B1 (fr) * | 2005-12-16 | 2012-10-05 | Lab Francais Du Fractionnement | Potentialisation de l'apoptose par des anticorps monoclonaux |
WO2007084672A2 (en) * | 2006-01-17 | 2007-07-26 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
USRE47123E1 (en) | 2006-07-18 | 2018-11-13 | Sanofi | EPHA2 receptor antagonist antibodies |
EP1933137A1 (fr) * | 2006-12-15 | 2008-06-18 | Glycode | Méthode d'investigation de la réponse à un traitement par un anticorps monoclonal |
DE602007013068D1 (de) * | 2006-09-13 | 2011-04-21 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
EP1918304A1 (en) * | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
MX2011001929A (es) * | 2008-08-26 | 2011-04-21 | Symphogen As | Tratamiento de trombocitopenia. |
US8529903B2 (en) | 2008-12-31 | 2013-09-10 | Bharat Serums And Vaccines Ltd. | Anti-RhD monoclonal antibodies |
US20110313137A1 (en) * | 2009-02-25 | 2011-12-22 | Dongxing Zha | Her2 antibody compositions |
FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
WO2010115553A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies |
PL2417156T3 (pl) | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trójwartościowe, bispecyficzne przeciwciała |
BRPI1012589A2 (pt) | 2009-04-07 | 2016-03-22 | Roche Glycart Ag | anticorpos bi-específicos anti-erbb-3/anti-c-met |
TWI513818B (zh) | 2009-06-02 | 2015-12-21 | Regeneron Pharma | 岩藻糖基化(fucosylation)-缺乏之細胞 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
MA33470B1 (fr) | 2009-08-14 | 2012-07-03 | Hoffmann La Roche | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone |
TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
SI2516457T1 (en) | 2009-12-21 | 2018-08-31 | Regeneron Pharmaceuticals, Inc. | MUSHROOM WITH HUMANIZED FC GAMES R |
US8883496B2 (en) | 2009-12-21 | 2014-11-11 | Regeneron Phamaceuticals, Inc. | Humanized FcgR mice |
AU2010335282B2 (en) | 2009-12-22 | 2015-05-21 | Roche Glycart Ag | Anti-HER3 antibodies and uses thereof |
FR2957598B1 (fr) | 2010-03-17 | 2015-12-04 | Lfb Biotechnologies | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
EP2563391B1 (en) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
RU2604811C2 (ru) | 2010-05-27 | 2016-12-10 | Мерк Шарп Энд Домэ Корп. | Способ получения антител с улучшенными свойствами |
CA2806148A1 (en) | 2010-07-30 | 2012-02-02 | Glycode | A yeast artificial chromosome carrying the mammalian glycosylation pathway |
AR082693A1 (es) | 2010-08-17 | 2012-12-26 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf |
BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
BR112013014522A2 (pt) | 2010-12-16 | 2017-09-26 | Roche Glycart Ag | anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
FR2971250A1 (fr) | 2011-02-07 | 2012-08-10 | Univ Nantes | Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
EP2681239B8 (en) | 2011-02-28 | 2015-09-09 | F. Hoffmann-La Roche AG | Antigen binding proteins |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
US9328170B2 (en) | 2011-05-25 | 2016-05-03 | Merck Sharp & Dohme Corp. | Method for preparing Fc containing polypeptides having improved properties |
FR2976811A1 (fr) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom |
JP5997151B2 (ja) | 2011-06-30 | 2016-09-28 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
WO2013013193A1 (en) | 2011-07-20 | 2013-01-24 | Zepteon, Incorporated | Polypeptide separation methods |
CN104302668A (zh) | 2011-09-23 | 2015-01-21 | 罗氏格黎卡特股份公司 | 双特异性的抗-egfr/抗igf-1r抗体 |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
FR2981946B1 (fr) | 2011-10-28 | 2015-02-20 | Lfb Biotechnologies | Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0) |
US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
CA3233142A1 (en) | 2011-11-30 | 2013-06-06 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
EP2812357B1 (en) | 2012-02-10 | 2020-11-04 | F.Hoffmann-La Roche Ag | Single-chain antibodies and other heteromultimers |
JP6203838B2 (ja) | 2012-06-27 | 2017-09-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用 |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
ES2896493T3 (es) | 2012-07-13 | 2022-02-24 | Roche Glycart Ag | Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
CA2882272C (en) | 2012-08-24 | 2023-08-29 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc region variant |
JP6437441B2 (ja) | 2012-11-02 | 2018-12-12 | ティージー セラピューティクス インコーポレイテッド | 抗cd20抗体およびpi3キナーゼ選択的阻害剤の組み合わせ |
FR3003172B1 (fr) * | 2013-03-15 | 2017-12-08 | Lab Francais Du Fractionnement | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
CA2894225A1 (fr) | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
JP2016508515A (ja) | 2013-02-13 | 2016-03-22 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 高ガラクトシル化抗TNF−α抗体およびその使用 |
TW201446962A (zh) | 2013-02-13 | 2014-12-16 | Lab Francais Du Fractionnement | 具有修飾的糖化作用之蛋白質及其製造方法 |
FR3003171B1 (fr) * | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
LT2970980T (lt) | 2013-03-15 | 2018-10-25 | Janssen Biotech, Inc. | Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
DK3031826T3 (da) | 2013-08-09 | 2018-12-17 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
WO2015073721A1 (en) | 2013-11-13 | 2015-05-21 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
KR102439412B1 (ko) | 2014-04-08 | 2022-09-02 | 리제너론 파아마슈티컬스, 인크. | 인간화된 Fc-감마 수용체를 갖는 비-인간 동물 |
FR3020063A1 (fr) | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
PT3148581T (pt) | 2014-05-30 | 2020-01-06 | Henlix Biotech Co Ltd | Anticorpos antirrecetor do fator de crescimento epidérmico (egfr) |
US10253109B2 (en) * | 2014-07-21 | 2019-04-09 | Bloodworks | Antibodies that recognize red blood cell antigens |
JP6707531B2 (ja) | 2014-09-09 | 2020-06-10 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体による併用療法 |
CA2968258A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
MX2017007208A (es) | 2014-12-04 | 2018-01-30 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de leucemia mieloide aguda. |
SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
EP3091033A1 (en) | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
EP3310386B1 (en) | 2015-06-22 | 2021-07-21 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
LT3827845T (lt) | 2015-11-03 | 2022-06-10 | Janssen Biotech, Inc. | Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
JP2019517991A (ja) | 2016-03-01 | 2019-06-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 低減したadcpを有するオビヌツズマブ及びリツキシマブ変異体 |
CA3024123A1 (en) | 2016-05-27 | 2017-11-30 | Tg Therapeutics, Inc. | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders |
EP3257866A1 (en) | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
FR3053688A1 (fr) | 2016-07-06 | 2018-01-12 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Mutants fc a activite fonctionnelle amelioree |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
KR20190068521A (ko) | 2016-09-09 | 2019-06-18 | 티지 쎄라퓨틱스, 인코포레이티드 | 혈액암을 치료하기 위한 항-cd20 항체, pi3 키나아제-델타 억제제, 및 항-pd-1 또는 항-pd-l1 항체의 조합 |
CA3041979A1 (en) | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
FR3064007A1 (fr) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
US20200148785A1 (en) * | 2017-03-29 | 2020-05-14 | Glycotope (GmbH) | Pd-l1 and ta-muc1 antibodies |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
PL3765525T3 (pl) | 2018-03-13 | 2023-12-27 | Zymeworks Bc Inc. | Koniugaty biparatopowe przeciwciało anty-her2 – lek i sposoby stosowania |
SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
JP7342701B2 (ja) | 2018-03-30 | 2023-09-12 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
PL237868B1 (pl) | 2018-04-04 | 2021-06-14 | Gdanski Univ Medyczny | Mutanty punktowe czynnika B oraz białka C2 do zastosowania do wzmacniania aktywności cytotoksycznej przeciwciał w leczeniu chorób nowotworowych |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
SG11202107941TA (en) | 2019-01-23 | 2021-08-30 | Encefa | Cd31 competitors and uses thereof |
CN110320352A (zh) * | 2019-07-25 | 2019-10-11 | 上海轩锋生物科技有限公司 | 基于抗体依赖的细胞介导细胞毒性的抗体效价检测方法 |
WO2021155295A1 (en) | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
BR112022018171A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
KR20220153621A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
CA3175137A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
KR20220152309A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
JPWO2021182574A1 (da) | 2020-03-12 | 2021-09-16 | ||
US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
JPWO2022270523A1 (da) | 2021-06-23 | 2022-12-29 | ||
BR112023026992A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
KR20240042415A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Ind Inc | Medicamento para el tratamiento y/o prevencion de cancer. |
WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
JPWO2023033129A1 (da) | 2021-09-03 | 2023-03-09 | ||
CN118369344A (zh) | 2021-09-16 | 2024-07-19 | 阿博莱斯制药公司 | 抗人cd45rc结合结构域及其用途 |
US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA406033A (en) | 1942-07-14 | American Can Company | Product packing apparatus | |
GB1382265A (en) | 1971-12-03 | 1975-01-29 | Ml Aviation Co Ltd | Transporters |
JPS56101171A (en) | 1980-01-16 | 1981-08-13 | Fuji Xerox Co Ltd | Separation failure detector for transfer paper |
EP0043718B1 (en) | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Improvements in or relating to cell lines |
EP0162918A1 (en) | 1983-11-28 | 1985-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8610106D0 (en) | 1986-04-25 | 1986-05-29 | Central Blood Lab Authority | Human igm-producing heterohybridoma |
FR2600076A1 (fr) | 1986-06-12 | 1987-12-18 | Fond Ctre Nal Transfusion | Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue |
JPS6350710A (ja) | 1986-08-21 | 1988-03-03 | Koputeitsuku:Kk | 光測定装置 |
GB8722019D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
GB8722020D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
GB8722018D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
DK0493446T3 (da) * | 1989-09-15 | 1997-08-11 | Tanox Biosystems Inc | Behandling af autoimmunsygdom. |
FR2653561A1 (fr) * | 1989-10-19 | 1991-04-26 | Fondation Nale Transfusion San | Hetero-anticorps anti-rhd et composition pharmaceutique les contenant. |
GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
US5272070A (en) * | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
US5558865A (en) | 1991-08-22 | 1996-09-24 | Nissin Shokuhin Kabushiki Kaisha | HIV immunotherapeutics |
US5880268A (en) | 1992-01-27 | 1999-03-09 | Icos Corporation | Modulators of the interaction between ICAM-R and αd /CD18 |
HUT68624A (en) | 1992-06-26 | 1995-07-28 | Aetsrn | Human monoclonal anti-rhesus (d) antibodies and cell lines producing same |
EP0598998B1 (en) * | 1992-09-07 | 2004-05-19 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies reacting with the ganglioside GM2 |
JP3565572B2 (ja) * | 1992-09-07 | 2004-09-15 | 協和醗酵工業株式会社 | ヒト化抗体 |
DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | Rekombinante anti-vla4 antikörpermoleküle |
CA2170034C (en) | 1993-08-24 | 2005-03-15 | Joseph William Harris | Recombinant humanized anti-human immunodeficiency virus antibody |
FR2724182B1 (fr) | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
AU690474B2 (en) * | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
RU2094462C1 (ru) | 1995-11-14 | 1997-10-27 | Оловникова Наталья Ивановна | Моноклональный иммуноглобулин человека класса iggi против антигена d системы резус |
US6440733B1 (en) * | 1996-02-15 | 2002-08-27 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel |
NZ333065A (en) | 1996-05-31 | 2000-05-26 | Sankyo Co | Treatment or prevention of autoimmune diseases using an insulin resistance improving thiazolidinedione derivative |
JPH10212247A (ja) * | 1996-05-31 | 1998-08-11 | Sankyo Co Ltd | 自己免疫疾患治療剤 |
AU722127B2 (en) | 1996-06-24 | 2000-07-20 | Zlb Behring Ag | Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens, the DNA encoding them and the process for their preparation and use |
JPH1080276A (ja) * | 1996-07-19 | 1998-03-31 | Mitsui Petrochem Ind Ltd | バイセクト糖鎖調節法 |
JPH10112531A (ja) | 1996-08-13 | 1998-04-28 | Hitachi Ltd | 半導体集積回路装置の製造方法 |
JP4550947B2 (ja) * | 1997-03-19 | 2010-09-22 | 協和発酵キリン株式会社 | ガングリオシドgm2に対するヒト型相補性決定領域(cdr)移植抗体 |
WO1999028349A2 (en) * | 1997-12-02 | 1999-06-10 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
DK2180007T4 (da) * | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
JP2000005908A (ja) | 1998-06-18 | 2000-01-11 | Sony Corp | 保持具、加工装置および加工方法 |
ES2571230T3 (es) * | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
EP2251426A1 (en) | 1999-10-26 | 2010-11-17 | Stichting Dienst Landbouwkundig Onderzoek | Mammalian-type glycosylation in plants |
AU2001236073B2 (en) | 2000-03-03 | 2006-10-19 | Kyowa Kirin Co., Ltd. | Gene recombinant antibody and its fragment |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
EP2314686B2 (en) | 2000-10-06 | 2023-06-21 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20060034829A1 (en) * | 2001-12-27 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
CA2481657A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
WO2003084569A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition anticorps |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
EP1666501A4 (en) * | 2003-08-11 | 2008-12-24 | Chugai Pharmaceutical Co Ltd | ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN |
US7150443B2 (en) | 2005-01-18 | 2006-12-19 | Mills Douglas W | Control valve for nitrous oxide injection system |
MX2008003054A (es) * | 2005-08-31 | 2008-03-25 | Centocor Inc | Lineas de celulas hospederas para la produccion de la region constante de anticuerpos, con fusion efectora mejorada. |
EP2245734B1 (en) | 2008-02-18 | 2014-07-02 | Freescale Semiconductor, Inc. | Mixer circuit |
-
2000
- 2000-04-12 FR FR0004685A patent/FR2807767B1/fr not_active Expired - Lifetime
-
2001
- 2001-04-12 EP EP10180551.3A patent/EP2341078B1/fr not_active Revoked
- 2001-04-12 EP EP15173391.2A patent/EP2947099A1/fr not_active Withdrawn
- 2001-04-12 ES ES04028814T patent/ES2525762T5/es not_active Expired - Lifetime
- 2001-04-12 WO PCT/FR2001/001127 patent/WO2001077181A2/fr active IP Right Grant
- 2001-04-12 EP EP01927974.4A patent/EP1272527B2/fr not_active Expired - Lifetime
- 2001-04-12 JP JP2001575651A patent/JP5192625B2/ja not_active Expired - Fee Related
- 2001-04-12 CA CA2406033A patent/CA2406033C/fr not_active Expired - Lifetime
- 2001-04-12 EP EP04028814.4A patent/EP1518864B2/fr not_active Expired - Lifetime
- 2001-04-12 AT AT01927974T patent/ATE419276T2/de active
- 2001-04-12 DK DK01927974.4T patent/DK1272527T4/da active
- 2001-04-12 DK DK10180551.3T patent/DK2341078T3/da active
- 2001-04-12 AU AU2001254858A patent/AU2001254858B2/en not_active Ceased
- 2001-04-12 DE DE60137210T patent/DE60137210D1/de not_active Expired - Lifetime
- 2001-04-12 ES ES01927974T patent/ES2320412T5/es not_active Expired - Lifetime
- 2001-04-12 US US10/257,477 patent/US7579170B2/en not_active Expired - Fee Related
- 2001-04-12 ES ES10180551.3T patent/ES2601241T3/es not_active Expired - Lifetime
- 2001-04-12 DK DK04028814.4T patent/DK1518864T4/da active
-
2005
- 2005-01-24 US US11/039,877 patent/US7931895B2/en not_active Expired - Fee Related
-
2006
- 2006-09-08 US US11/517,525 patent/US7541029B2/en not_active Expired - Lifetime
-
2007
- 2007-05-08 AU AU2007202060A patent/AU2007202060B2/en not_active Ceased
-
2009
- 2009-07-14 US US12/502,915 patent/US8153124B2/en not_active Expired - Fee Related
- 2009-07-14 US US12/502,911 patent/US8124078B2/en not_active Expired - Fee Related
- 2009-07-14 US US12/502,920 patent/US8178093B2/en not_active Expired - Fee Related
-
2010
- 2010-12-23 AU AU2010257417A patent/AU2010257417B2/en not_active Ceased
-
2011
- 2011-03-31 US US13/077,644 patent/US8685725B2/en not_active Expired - Fee Related
-
2012
- 2012-03-30 US US13/436,114 patent/US8409572B2/en not_active Expired - Lifetime
- 2012-04-10 US US13/443,532 patent/US8357370B2/en not_active Expired - Lifetime
- 2012-06-06 JP JP2012128845A patent/JP5722278B2/ja not_active Expired - Lifetime
- 2012-06-06 JP JP2012128847A patent/JP5837859B2/ja not_active Expired - Lifetime
- 2012-06-06 JP JP2012128846A patent/JP5722279B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-15 JP JP2013103336A patent/JP5788432B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-16 US US14/157,061 patent/US9708409B2/en not_active Expired - Lifetime
-
2015
- 2015-02-09 US US14/617,836 patent/US9718889B2/en not_active Expired - Lifetime
- 2015-04-01 US US14/676,508 patent/US9718890B2/en not_active Expired - Lifetime
- 2015-08-21 JP JP2015163589A patent/JP6124958B2/ja not_active Expired - Lifetime
- 2015-08-21 JP JP2015163588A patent/JP2015221827A/ja active Pending
-
2016
- 2016-10-11 JP JP2016199815A patent/JP2017012199A/ja active Pending
-
2017
- 2017-06-07 US US15/616,596 patent/US10081683B2/en not_active Expired - Fee Related
- 2017-09-11 JP JP2017174012A patent/JP2017214427A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2525762T3 (es) | Composición de anticuerpos con alta ADCC | |
WO2004058797A3 (en) | Human monoclonal antibodies against interleukin 8 (il-8) | |
CN107531793B (zh) | 对人类cd19具有专一性的抗体药剂和其用途 | |
JP2018046872A5 (da) | ||
WO2004045512A3 (en) | Human monoclonal antibodies against cd25 | |
WO2003040169A3 (en) | Human monoclonal antibodies to dendritic cells | |
CA2380783A1 (en) | Human monoclonal antibodies to prostate specific membrane antigen | |
WO2004043989A3 (en) | Human monoclonal antibodies to heparanase | |
KR20200139189A (ko) | 다가 항체 | |
ATE208820T1 (de) | Humanisierte antikoerper | |
NO20040752L (no) | Humane antistoffer spesifikke for interleukin 15 (IL-15) | |
AU2004215120A8 (en) | Human antibodies specific for interleukin 15 (IL-15) | |
AU8727291A (en) | Bispecific antibodies, method of production, and uses thereof | |
HK1059442A1 (en) | Human monoclonal antibodies to dendritic cells | |
RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
Teillaud | Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges | |
DK0493446T3 (da) | Behandling af autoimmunsygdom. | |
KR20210111767A (ko) | 절단된 다가 다량체 | |
Leibiger et al. | Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma | |
Donadel et al. | Human polyreactive and monoreactive antibodies: effect of glycosylation antigen binding | |
Holzlöhner et al. | Generation of murine monoclonal antibodies with specificity against conventional camelid IgG1 and heavy-chain only IgG2/3 | |
Chin et al. | Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell | |
AU2004283925A1 (en) | Use of metallic cations to improve functional activity of antibodies | |
Björklund et al. | Characterisation of recombinant human IgE-Fc fragments expressed in baculovirus-infected insect cells | |
Jar et al. | Mouse× pig chimeric antibodies expressed in Baculovirus retain the same properties of their parent antibodies |